Cancer situation in China: an analysis based on the global epidemiological data released in 2024

Abstract

Background: Cancer remains a major cause of mortality and a significant economic burden in China. Exploring the disparities in cancer patterns and control strategies between China and developed countries may offer valuable insights for policy formulation and enhance cancer management efforts. This study examined the incidence, mortality, and disability-adjusted life year (DALY) burden of cancer in China, and compared these metrics with those observed in the United States (US) and the United Kingdom (UK).

Methods: Data on cancer incidence, mortality, and DALYs for China, the US, and the UK were sourced from the GLOBOCAN 2022 online database and the Global Burden of Disease 2021 study (GBD 2021). We utilized Joinpoint regression models to analyze trends in cancer incidence and mortality across these countries, calculating annual percent changes (APCs) and determining the optimal joinpoints.

Results: In 2022, China recorded around 4,824,703 new cancer cases and 2,574,176 cancer-related deaths, contributing to 71,037,170 DALYs. China exhibited a lower cancer incidence rate compared to the US and the UK. Although cancer-related mortality in China is slightly lower than that in the UK, it is significantly higher than that in the US. Additionally, China experienced significantly higher DALY rates compared to both the US and UK. The cancer landscape in China was also undergoing significant changes, with a rapid rise in the incidence and burden of lung, colorectal, breast, cervical, and prostate cancers. Meanwhile, the incidence and burden of stomach cancer continued to decline. Although the incidence of liver and esophageal cancers was decreasing, the burden of liver cancer was increasing, while the burden of esophageal cancer remained largely unchanged.

Conclusions: The cancer profile of China is shifting from that of a developing country to one more typical of a developed country. The ongoing population aging and the rise in unhealthy lifestyles are expected to further escalate the cancer burden in China. Consequently, it is crucial for Chinese authorities to revise the national cancer control program, drawing on successful strategies from developed countries, while also accounting for the regional diversity in cancer types across China.

Keywords

cancer pattern / China / disability-adjusted life year / GBD 2021 / GLOBOCAN 2022 / incidence / mortality / risk factor / United Kingdom / United States

References

[1] DiseasesGBD, Injuries C. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440): 2133-2161.

[2] World Health Organization. Global Health Observatory. Geneva. Accessed: June 2024. http://www.who.int/data/gho

[3] BrayF, Laversanne M, SungH, FerlayJ, SiegelRL, SoerjomataramI, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[4] CollaboratorsGBDCRF. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022; 400(10352): 563-591.

[5] QiuH, CaoS, XuR. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021; 41(10): 1037-1048.

[6] FengR, SuQ, HuangX, Basnet T, XuX, YeW. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Cancer Commun (Lond). 2023; 43(1): 75-86.

[7] ChenP, LiuY, WenY, ZhouC. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022; 42(10): 937-970.

[8] TaoX, LiT, GandomkarZ, Brennan PC, ReedWM. Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries. Asia Pac J Clin Oncol. 2023; 19(6): 645-654.

[9] SunC, LiuY, HuangY, Li B, RangW. Colorectal Cancer Incidence and Mortality Trends and Analysis of Risk Factors in China from 2005 to 2015. Int J Gen Med. 2021; 14: 9965-9976.

[10] LiuX, YuC, BiY, ZhangZJ. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health. 2019; 172: 70-80.

[11] WangF, Mubarik S, ZhangY, WangL, WangY, YuC, et al. Long-Term Trends of Liver Cancer Incidence and Mortality in China 1990-2017: A Joinpoint and Age-Period-Cohort Analysis. Int J Environ Res Public Health. 2019; 16(16): 2878.

[12] GaoK, WuJ. National trend of gastric cancer mortality in China (2003-2015): a population-based study. Cancer Commun (Lond). 2019; 39(1): 24.

[13] GuoD, JinJ, LiD, HeY, LinY. Analysis of the incidence and mortality trends of esophageal cancer in cancer registry areas of China and Japan. Int J Cancer. 2024; 155(8): 1376-1386.

[14] LiS, HuangM, ZhuY, ZengH, ZhangF. Temporal trends in incidence and mortality of cervical cancer in China from 1990 to 2019 and predictions for 2034. Eur J Cancer Prev. 2024; 33(3): 252-261.

[15] Global Cancer Observatory: Cancer Today [Internet]. Lyon. 2024 [cited June 2024].

[16] The Institute for Health Metrics and Evaluation. Global Burden of Disease. 2024. Accessed: June 2024. https://www.healthdata.org/research-analysis/gbd

[17] CollaboratorsGBDRF. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440): 2162-2203.

[18] KimHJ, FayMP, FeuerEJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3): 335-351.

[19] SunD, LiH, CaoM, HeS, LeiL, PengJ, et al. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020; 17(4): 879-895.

[20] AllemaniC, Matsuda T, Di CarloV, HarewoodR, MatzM, NiksicM, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023-1075.

[21] ChenRC, HaynesK, DuS, BarronJ, KatzAJ. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA Oncol. 2021; 7(6): 878-884.

[22] WillemsB, Cullati S, PrezV, JolidonV, Burton-Jeangros C. BrackeP. Cancer Screening Participation and Gender Stratification in Europe. J Health Soc Behav. 2020; 61(3): 377-395.

[23] YipW, FuH, ChenAT, Zhai T, JianW, XuR, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet. 2019; 394(10204): 1192-1204.

[24] LuZ, ChenY, LiuD, JiaoX, LiuC, WangY, et al. The landscape of cancer research and cancer care in China. Nat Med. 2023; 29(12): 3022-3032.

[25] BasuP, PontiA, AnttilaA, Ronco G, SenoreC, ValeDB, et al. Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report. Int J Cancer. 2018; 142(1): 44-56.

[26] AhmadAS, OffmanJ, DelonC, North BV, SheltonJ, SasieniPD. Years of life lost due to cancer in the United Kingdom from 1988 to 2017. Br J Cancer. 2023; 129(10): 1558-1568.

[27] HallIJ, TangkaFKL, SabatinoSA, Thompson TD, GraubardBI, BreenN. Patterns and Trends in Cancer Screening in the United States. Prev Chronic Dis. 2018; 15: E97.

[28] ByrneS, BoyleT, AhmedM, Lee SH, BenyaminB, HypponenE. Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types. Int J Epidemiol. 2023; 52(3): 817-826.

[29] HopkinsonNS. Smoking and lung cancer-70 long years on. BMJ. 2024; 384: q443.

[30] ShielsMS, Graubard BI, McNeelTS, KahleL, Freedman ND. Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the United States, 1991-2018. J Natl Cancer Inst. 2024; 116(5): 711-716.

[31] National Cancer Institute. Online Summary of Trends in US Cancer Control Measures: Prevention. Accessed: June 2024. https://progressreport.cancer.gov/prevention

[32] KratzerTB, BandiP, FreedmanND, Smith RA, TravisWD, JemalA, et al. Lung cancer statistics, 2023. Cancer. 2024; 130(8): 1330-1348.

[33] DubeyAK, GuptaU, JainS. Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis. Chin J Cancer. 2016; 35(1): 71.

[34] PalaliA, van Ours JC. The impact of tobacco control policies on smoking initiation in eleven European countries. Eur J Health Econ. 2019; 20(9): 1287-1301.

[35] ChanKH, XiaoD, ZhouM, Peto R, ChenZ. Tobacco control in China. Lancet Public Health. 2023; 8(12):e1006-e15.

[36] Chinese center for disease control and prevention. 2024. Accessed: June 2024. https://en.chinacdc.cn/

[37] HuangJ, DengY, TinMS, Lok V, NgaiCH, ZhangL, et al. Distribution, Risk Factors, and Temporal Trends for Lung Cancer Incidence and Mortality: A Global Analysis. Chest. 2022; 161(4): 1101-1111.

[38] WangJB, FanYG, JiangY, Li P, XiaoHJ, ChenWQ, et al. Attributable causes of lung cancer incidence and mortality in China. Thorac Cancer. 2011; 2(4): 156-163.

[39] Han-YouX. Chronic infection and other risk factors of cancer in China and other countries. Ann Oncol. 2013; 24(1): 267.

[40] LiouJM, Malfertheiner P, SmithSI, El-OmarEM. WuMS. 40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention. Lancet. 2024; 403(10444): 2570-2572.

[41] LiY, ChoiH, LeungK, Jiang F, GrahamDY, LeungWK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023; 8(6): 553-564.

[42] ShresthaR, Koirala K, RajKC, BatajooKH. Helicobacter pylori infection among patients with upper gastrointestinal symptoms: prevalence and relation to endoscopy diagnosis and histopathology. J Family Med Prim Care. 2014; 3(2): 154-158.

[43] LiM, SunY, YangJ, de Martel C, CharvatH, CliffordGM, et al. Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta-analysis. Helicobacter. 2020; 25(5): e12729.

[44] CaoM, FanJ, LuL, FanC, WangY, Chen T, et al. Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years. Cancer Lett. 2022; 536: 215652.

[45] BurtonA, TataruD, DriverRJ, Bird TG, HuwsD, WallaceD, et al. Primary liver cancer in the UK: Incidence, incidence-based mortality. and survival by subtype, sex, and nation. JHEP Rep. 2021; 3(2): 100232.

[46] El-SeragHB, MasonAC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000; 160(21): 3227-3230.

[47] BhatlaN, Singhal S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2020; 65: 98-108.

[48] de SanjoseS, QuintWG, AlemanyL, Geraets DT, KlaustermeierJE, LloverasB, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048-1056.

[49] SinghD, VignatJ, LorenzoniV, Eslahi M, GinsburgO, Lauby-SecretanB. et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023; 11(2): e197-e206.

[50] ArbynM, Weiderpass E, BruniL, de SanjoseS, Saraiya M, FerlayJ, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8(2): e191-e203.

[51] JiMF, ShengW, ChengWM, Ng MH, WuBH, YuX, et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol. 2019; 30(10): 1630-1637.

[52] FarrellPJ. Epstein-Barr Virus and Cancer. Annu Rev Pathol. 2019; 14: 29-53.

[53] ChoiJW, HuaTNM. Impact of Lifestyle Behaviors on Cancer Risk and Prevention. J Lifestyle Med. 2021; 11(1): 1-7.

[54] DiaoX, LingY, ZengY, Wu Y, GuoC, JinY, et al. Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019. Cancer Commun (Lond). 2023; 43(11): 1229-1243.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.